

Snowdome Foundation Annual Review 2024/25



Snowdome
Foundation™

Making hope real

Making Hope Real

Snowdome Foundation is the leading not-for-profit organisation focused exclusively on raising funds to support translational research into blood cancers.

When combined, blood cancers are the third highest cause of cancer death in Australia. Each year more than 19,500 Australian adults and children are newly diagnosed with a blood cancer; myeloma, lymphoma or leukaemia.

Alarming, this number is predicted to more than double by 2035. Unlike other cancers, routine screening, lifestyle changes and public awareness campaigns will not reduce a person's risk of developing a blood cancer.

But there is hope.

Snowdome works with visionary donors and inspiring researchers and clinicians to shape the future of blood cancer treatments in Australia and create positive outcomes for patients. Founded in 2010, Snowdome has been at the forefront of precision medicine, championing the adoption of genomic testing, the revolution of harnessing a patient's own immune system through CAR T-cell therapy and funding innovative research and clinical trials.

Vision

Our vision is to give every Australian blood cancer patient the best opportunity for a cure.

Mission

Snowdome's mission is to accelerate next-generation treatments for Australian blood cancer patients to help them live longer, better lives.

Contents

Message from the Chair and Chief Executive	6	Snowball 2025 – Coming full circle	24
15 Years of the Snowdome Foundation	8	Snowball Event Partners and Sponsors	26
GURNER™ Snowdome Immunotherapy Fellowship	10	Events	27
Epworth Centre for Immunotherapies and Snowdome Laboratories	12	Honouring the Past and Funding the Future of Blood Cancer Research	28
2025 Klempfner Snowdome Fellowship	14	Financials 2024–25	30
Cannon Family Travel Grants	16	Board	36
2025 Research Grant Awards	18	Executive	38
Celebrating 15 Years of Advancing Exceptional Research	19	Committees	39
Making Hope Real	20	Partners and Collaborators	40
Australasian Lymphoma Alliance	22	ESG Compliance	41
		Thank You	42
		Dedication	43

Message from the Chair and Chief Executive

It is with immense pride that we share our 2025 Annual Review, reflecting on a year of remarkable achievements and milestones, while reaffirming our commitment to ensuring every Australian blood cancer patient has the best opportunity for a cure.

Snowdome turned 15 this year, providing us with an opportunity to reflect on the personal stories that inspired the Snowdome Foundation. Founded by Grant Rutherford, Rob Tandy and Prof. Miles Prince AM, these stories inspired a ripple that has made Snowdome into what it is today, an organisation that is made up of hundreds of personal stories and has positively impacted the lives of thousands of Australian blood cancer patients and their families.

We celebrated this ripple effect at Snowball 2025, where the Chloe Rutherford Paediatric Haematology Fellowship and the John Tandy Myeloma Haematology Fellowship were announced.

In just 15 years, Snowdome has enabled \$95 million to be invested in blood cancer research. This investment has seen 84 research grants awarded, supporting more than 105 research positions.

Thanks to the generous philanthropy of our donors, we further strengthened our impact on blood cancer research during 2025, awarding three new research grants and an additional two Cannon Family Travel Grants. We have also continued to fund existing grant commitments which have reinforced Snowdome's role at the forefront of innovative immunotherapy research.



John Salvaris
Chair



Vincent Ramos
Chief Executive

None of our accomplishments would have been possible without the dedication of our Board of Directors, Executive Team, the generosity and trust of our donors, every partner and supporter, and the incredible Snowdome researchers and clinicians.

We also extend our heartfelt thanks to Kirstee Macbeth who concluded an exemplary tenure as Chief Executive at the end of 2025. Kirstee's exceptional leadership and significant contributions were instrumental in Snowdome's achievements this year.

15 Years of the Snowdome Foundation

Since 2010, Snowdome has...

Enabled more than **\$95m** to be invested in blood cancer research

Funded **84** research projects

Enabled thousands of patients to participate in over **125** clinical trials

Enabled **105** research positions

In 2025...

\$2.94m was granted to research projects

\$550k was raised at Snowball 2025

30 lymphoma patients received access to lifesaving, unsubsidised therapies through funds raised at Snowball 2024

Membership of the ALA grew by **17%**



GURNER™ Snowdome Immunotherapy Fellowship

In 2025, Dr Brian Grainger was awarded the GURNER™ Snowdome Immunotherapy Fellowship, joining the multidisciplinary team of clinicians and scientists at the Epworth Centre for Immunotherapies and Snowdome Laboratories (ECISL) to advance research in novel immune therapies including Chimeric Antigen Receptor T-cell (CAR T) therapy.

Across the world, CAR T-cell therapy has shown outstanding responses in patients with otherwise incurable blood cancers. However, there are major barriers to curing all lymphoma patients with CAR T-cell therapy in Australia, including accessibility, cost and efficacy.

Dr Grainger will assist the team at Epworth Healthcare to develop and write the trial protocols, along with ethics and regulatory (Therapeutic Goods Administration) applications for a new CAR T-cell therapy approach, analyse data and support publications that will address these challenges.

Through research aided by the GURNER™ Snowdome Immunotherapy Fellow, Dr Grainger will also investigate the gut microbiome of myeloma patients and the bacterial causes of diarrhoea in patients undergoing stem cell transplants. This will

address a key issue of endemic issues in stem cell transplants after which 91 percent of all patients report debilitating stomach and gut problems as a result. Following and monitoring 40 patients across a two-year timeframe, it is hoped the research will lead to reduced hospital stays, improved comfort, and remove complications for stem cell transplant patients.

For GURNER™ Group founder Tim Gurner, the fellowship has a uniquely personal meaning. His father, Colin Gurner, passed away from multiple myeloma when Tim was just 19 years of age. Colin was a patient of leading haematologist and one of Snowdome Foundation's co-founders and directors, Professor Miles Prince AM. Tim and Prof. Prince have remained close over the years, with the GURNER™ Foundation now committed to supporting this groundbreaking research project for three years.



Tim Gurner
and Aimee Gurner

“This is critical research into a rare but debilitating form of cancer. When my dad passed away it was quick, and brutal. My hope is that one day no-one should go through what my family endured, watching my dad deteriorate so quickly.”

— Tim Gurner

Epworth Centre for Immunotherapies and Snowdome Laboratories

The Epworth Centre for Immunotherapies and Snowdome Laboratories (ECISL) continues to build on its success as a world-class centre of excellence in blood cancer treatment.



Launched in 2021, ECISL was made possible through a \$13 million partnership between the Epworth Medical Foundation and the Snowdome Foundation and is 100 per cent donor-funded.

ECISL aims to increase access to innovative cancer treatments and contribute to the global progress of blood cancer therapies through the delivery of research, clinical trials and education in immunotherapies.

Immunotherapies, and in particular CAR T-cell therapy, are one of the most revolutionary advances in the treatment of cancer in recent years. ECISL plays a pioneering role in providing access to CAR T-cell therapies through clinical trials so Australians do not have to travel overseas to access potentially life-saving treatment that they are either ineligible to receive in Australia or that is not available here.

In 2025, 23 clinical trials were actively recruiting patients at ECISL, with a further 8 trials in development. These innovative trials not only shape the future of blood cancer treatment globally but also change the lives of patients through prompt access to groundbreaking therapies.

The first patient in Australia treated with allogeneic CAR T-cells in a clinical trial at ECISL in 2025 is now in complete remission. Diagnosed with angioimmunoblastic T-cell lymphoma (AITL) in April 2022, the patient's disease progressed after four cycles of standard therapy. The patient then underwent



salvage therapy, requiring monthly treatment for three years, but in June 2025, the disease progressed again with no effective standard-of-care options available.

The patient travelled from interstate to ECISL to participate in this cutting-edge clinical trial, a drastic improvement on the burden of international travel that would have been required previously. The patient received allogeneic, or "off-the-shelf" CAR T-cells derived from healthy donors, which offer benefits such as faster access to treatment and lower manufacturing costs.



One month after receiving the allogeneic CAR T-cells, the patient was considered to have a complete response. Three months later, and after returning to their home state, the patient's scans confirm an ongoing remission, and for the first time in more than three years, this patient does not require any ongoing therapy.

This story is one of the hundreds in which ECISL has made hope real for patients, through access to innovative clinical trials. Reflecting on the Centre's achievements so far, Professor Miles Prince AM, Director of Molecular Oncology and Cancer Immunology, commented that "the treatments for blood cancers are improving rapidly and to give our patients the best chance we have to get these new treatments to patients as quickly as we can. The fastest and most effective way is often through clinical trials. I am proud to say that at ECISL we have world-class facilities and a team of experts that can deliver these amazing life-changing treatments to our patients."

2025 Klempfner Snowdome Fellowship

In August, Snowdome proudly announced the 2025 Klempfner Snowdome Fellowship, led by Prof. Mark Dawson at the Peter MacCallum Cancer Centre.



Prof. Mark Dawson

This fellowship represents a significant investment in advancing next-generation Chimeric Antigen Receptor (CAR) T-cell therapy, one of the most transformative innovations in blood cancer treatment.

CAR T-cell therapy works by reprogramming a patient's T cells (a type of immune cell) to target and kill cancer cells with unparalleled precision. Although 80 per cent of patients receiving CAR T-cell therapy achieve remission, more than 50 per cent of these patients will ultimately relapse. **Improving the durability and effectiveness of CAR T-cell therapy is a critical priority for researchers.**

The 2025 Klempfner Snowdome Fellowship addresses a key challenge in CAR T-cell therapy. T cells retrieved from patients to manufacture CAR T products are often impaired by the patient's prior treatments including chemotherapy and radiotherapy, which can lead to CAR T-cell therapy failure.

Under the mentorship of Prof. Dawson, two clinician-scientists, Dr Phillip Nguyen and Dr Tessa Potenzy, will develop strategies to generate CAR T-cells from blood stem cells that freshly produce T-cells in the patient. This circumvents the use of impaired T-cells and instead offers a diverse, non-compromised population of functional T-cells. This involves developing the ability to expand blood stem cells and engineer them into more effective anti-cancer cellular therapies.

Dr George Klempfner and Dr Yolanda Klempfner AO initially met Prof. Mark Dawson in 2006, before reconnecting with him in 2014 and learning about his remarkable impact on blood cancer research.

They subsequently began supporting his research through the Snowdome Foundation, and this year marks a significant milestone, a decade of remarkable generosity from the Klempfner family. Since 2015, the Klempfner family has supported six research projects, enabling research into a diagnostic tool called ctDNA for myelodysplastic syndromes, a clinical trial for a new blood cancer targeted therapy, and projects to improve the success rates of bone marrow transplants and CAR T-cell therapy. The collaboration is a perfect showcase of the powerful connection Snowdome creates between visionary philanthropic donors and Australia's brightest research minds.

Prof. Dawson said, "the enduring support of George and Yolanda Klempfner has underpinned the training and career development of several amazing clinician-scientists. It is a huge privilege that they have entrusted to the Dawson Lab and I am so very grateful for their support."

At the American Society of Hematology (ASH) awards in December, Prof. Dawson was awarded the William Dameshek Prize for his contributions to the understanding of epigenetics in blood cancer research. Of incredible significance, he is the first Australian scientist to receive this honour, rarely awarded outside of the US.

Cannon Family Travel Grants

The Cannon Family Travel Grants were established through the estate of Dr Bob Cannon OAM and Dr Jean Cannon after their daughter Jill was diagnosed with multiple myeloma in 2011.

The grants provide Australian blood cancer researchers with the opportunity to travel to broaden their knowledge, exchange ideas, establish collaborations and bring back valuable insights that can contribute to the advancement of blood cancer research in Australia.

Dr Edward Cliff

Dr Edward Cliff is a third-year clinical haematology registrar at the Peter MacCallum Cancer Centre and Royal Melbourne Hospital. He was awarded a Cannon Family Travel Grant to attend the American Society of Haematology (ASH) Annual Meeting in California.

Dr Cliff presented an oral presentation on *Cell of Origin Differential Efficacy of Polatuzumab Vedotin in Diffuse Large B-cell Lymphoma* as well as two research posters focusing on multiple myeloma and second primary malignancies in lymphoma patients. He was also a senior author on two additional posters, one exploring patient preferences in multiple myeloma treatments and another focusing on global access to CAR T cells and disparities between high income countries.

The ASH Annual Meeting is globally recognised as the largest and most comprehensive haematology event, attracting around 30,000 attendees from more than 100 countries each year.



Dr Hansen Kosasih

Dr Hansen Kosasih is a Senior Research Officer specialising in cancer genomics, precision medicine, and functional genomics of paediatric leukemia at the Children's Cancer Institute, Sydney.

Dr Kosasih used his Cannon Family Travel Grant to attend the 2025 Gordon Research Conference: Cancer Genetics and Epigenetics in Italy. He presented a poster and sought expert feedback on his research into paediatric acute lymphoblastic leukaemia (ALL), the most common form of childhood cancer. He gained a multitude of insights that will help strengthen the direction of his research in this area.

The 2025 Gordon Research Conference showcased the latest developments in cancer genetics and epigenetics, both of which aid researchers to identify the causes of cancer, predict which patients will respond to certain therapies and design more precise treatments with fewer side effects.



Grants

2025 Research Grant Awards

In 2025, Snowdome awarded the following grants to exceptional researchers pursuing innovative approaches to blood cancer research and treatments.



Dr Criselle D'Souza: Developing a new cellular immunotherapy for T cell lymphoma



Prof. Mark Dawson: Klempfner Snowdome Fellowship



Dr Brian Grainger: GURNER™ Snowdome Immunotherapy Fellowship



Dr Paniz Tavakoli: Cannon Family Travel Grant



Dr Helen Cashman: Cannon Family Travel Grant

Grants

Celebrating 15 Years of Advancing Exceptional Research

Snowdome is committed to supporting Australia's leading researchers and clinicians in their pursuit of innovative, next-generation blood cancer treatments.

Over the last 15 years, Snowdome has funded 84 multi-year research projects, enabling 105 research positions. We are dedicated to funding inspirational researchers who have clear visions and are as passionate about finding a cure for blood cancer as we are.

A/Prof Mary Ann Anderson
 Prof Paul Beavis
 A/Prof Piers Blombery
 A/Prof Charles de Bock
 Prof Richard Boyd
 Dr Nicole Brooks
 Dr Imogen Caldwell
 Dr Helen Cashman
 Prof Chan Cheah
 Dr Edward Cliff
 Dr Patrick Connerty
 Dr Katherine Cummins
 Prof Mark Dawson
 Dr Carrie van der Weyden
 Dr Criselle D'Souza
 Dr Jennifer Devlin
 Prof Michael Dickinson
 Dr Pilar Dominguez
 Dr Katie Fennell
 Dr Salvatore (Sam) Fiorenza

Dr Lucy Fox
 Dr Clare Gould
 Dr Brian Grainger
 Dr Gareth Gregory
 Prof Sean Grimmond
 A/Prof Carolyn Grove
 Dr Belinda Guo
 Prof Eliza Hawkes
 James Hicks
 Prof Ricky Johnstone
 A/Prof Lev Kats
 A/Prof Melita Kenealy
 A/Prof Amit Khot
 Tracy King
 Dr Hansen Kosasih
 Dr Jamie Kuzich
 Emily Li
 Prof Richard Lock
 Dr Kylee Maclachlan
 Prof Ravi Majeti
 Dr Jacek Marzec
 Dr Adrian Minson

Dr Elizabeth Moore
 Prof Charles Mullighan
 Dr Niles Nelson
 Prof Stephen Nutt
 Prof Jane Oliaro
 Dr Michael Osborn
 Dr Anna Piggini
 Prof John Pimanda
 Prof Miles Prince AM
 Dr Indu Raman
 Dr Matthew Rees
 Prof David Ritchie
 Dr David Ross
 Prof Andrew Roberts AM
 Dr Muhammed B. Sabdia
 Prof Jake Shortt
 Prof Andrew Spencer
 Prof Jeff Szer AM
 Dr Peter Tan
 Dr Paniz Tavakoli
 Dr Siok Tey
 Prof Daniel Thomas

Dr Ella Thompson
 Dr Joshua Tobin
 Prof Judith Trotman
 Dr Ashwin Unnikrishnan
 Dr Kate Vandyke
 Dr Meaghan Wall
 Prof Andrew Wei
 A/Prof David Westerman
 Dr Simon Willis
 Dr Colin Wood
 Dr Simon Wu
 A/Prof Costas Yannakou
 Dr Paul Yeh
 Dr Jessie Zhao

Making Hope Real

The Snowdome Foundation gratefully acknowledges the following major donors, foundations and estates for their generous contributions in 2025 and for making hope real for Australians living with blood cancer.

Major Donors

Peter and Sarndi Addison
Cannon Family
Tony and Helen Gandel
Peter and Rae Gunn
Tim and Aimee Gurner
Mike and Jackie Haintz
Drs George Klempfner and Yolanda Klempfner AO
Harvey and Janette Lewis
Kirsten MacLeod and James Orloff
Ian and Jane Mandie
Paul and Clare McCann – Newmagoo Family Trust
Helen Nicolay
Wendy Peter
Rosemary Pitt
Ian and Virginia Rehfisch
Rodney and Ann Smorgon Family
Rob and Lou Tandy
Hendrikus and Debbie Verhagen
Peter and Rachel Vodicka - Bird Family Foundation
Bruce Wilson
Russell and Diane Withers

Philip and Trix Wollen
Yueh-Chuan Yu

Foundations

Belford Foundation
The Calvert-Jones Foundation
Gillespie Family Foundation
GP Harris Foundation
GURNER™ Foundation
Harbig Family Foundation
Jan and Robert Lyng Charitable Fund
The McNamara Family Foundation
Morris Family Foundation
Mostyn Family Foundation
The Pratt Foundation
Rae and Peter Gunn Family Foundation
The Samuel Nissen Charitable Foundation
Silberscher Family Foundation
Tour de Cure
The Wolf Foundation

Estates

Estate of Marjorie May Kingston

Fundraisers

Snowdome would like to acknowledge Geoff Nyssen (MY Fun Run Mount Eliza) and the family and friends of Tim Sim and the Black Rock Football Club for their wonderful fundraising efforts in 2025. We also extend our heartfelt thanks to the numerous individuals and families who donated or raised funds in memory of a loved one or in lieu of gifts for us throughout the year and those who wish to remain anonymous.

Leave a lasting gift

We would like to thank and acknowledge those individuals who have shared with us that they have left a gift to the Snowdome Foundation in their Will.

By including us in your Will or Trust, you and your family can play a vital role in funding life-changing research and next-generation treatments for Australian blood cancer patients.

Gifts in Wills, both large and small, are a unique and powerful way to provide for causes you believe in, and ensure that your legacy is honoured into the future.

Once you have provided for your loved ones, please consider including the Snowdome Foundation in your Will. The process of including a gift in your Will is straightforward, and further information is available on our website should you wish to learn more.

Collaborating to shape better care

Australasian Lymphoma Alliance

Snowdome proudly supports the Australasian Lymphoma Alliance (ALA).



ALA Breakfast at BLOOD 2025

The ALA is a collaboration of lymphoma clinicians who share research, practice and findings to better shape the care of lymphoma patients.

Members range from registrars and nurses through to pharmacists and professors, from haematology, oncology and radiation oncology backgrounds.



AUSTRALASIAN LYMPHOMA ALLIANCE

Led by Dr Pietro Di Ciaccio, as Chair of the Alliance, membership base has grown by 17 per cent during the year to 170 members, including six New Zealand, three Singapore and one Japan based clinician. All Australian states are represented, ensuring Australian clinicians can easily access expert advice and opinions in determining diagnosis and treatment pathways.

Achievements for ALA members in 2025 included:

- New consensus practice statement published for Mantle Cell Lymphoma
- 27 members contributed to abstracts presented at the European Hematology Association conference
- 32 members contributed to abstracts presented at the 18th International Conference on Malignant Lymphoma Lugano

- 74 members contributed to abstracts presented at the American Society of Hematology conference
- 89 members contributed to abstracts presented at the BLOOD conference in Perth, with 14 oral presentations
- Over 60 patient cases were presented at the Australasian T-Cell Lymphoma Network fortnightly eGrand Rounds, making a real impact on patient care across the Asia-Pacific region and reaching an audience of more than 400.

In May, the ALA hosted an Educational Webinar. Six expert panelists discussed and explored three ALA Consensus Practice Statements:


- Marginal zone lymphomas
- Diagnosis, management and follow-up of follicular lymphoma

- Diagnosis and management of mantle cell lymphoma

In October 2025, another successful Lymphoma Interest Group Breakfast was held during the Blood Conference in Perth. Co-hosted with the Lymphoma and Related Diseases Registry (LaRDR) and Lymphoma Australia, the event was attended by over 90 guests face-to-face, with a small number joining virtually.

The ALA continues to improve outcomes for lymphoma patients through the collaboration and sharing of expertise, experience and knowledge. Since the ALA was formed, there has been close to 30 publications by early career researchers, 16 educational webinars, 12 Consensus Practice Statements written and five breakfast meetings held with LaRDR and Lymphoma Australia.

Summary of Case Diagnoses, 2025 eGrand Rounds



- Mycosis fungoides – 17
- Peripheral T-Cell Lymphoma (PTCL), Not Otherwise Specified – 9
- Sezary syndrome – 2
- Panniculitis T-Cell – 3
- Natural Killer (NK) T-cell Lymphoma – 8
- DiGeorge Syndrome and AITL – 2
- ALK Negative Anaplastic Large Cell Lymphoma – 3
- Refractory PTCL – 2
- Non-Hodgkin lymphoma – 2
- Other – 6

Coming full circle

Concluding our Snowball trilogy, Snowball 2025 celebrated the power of the ripple effect.

What starts as a donation to blood cancer research can spark something extraordinary. Just like dropping a single stone into still water, the ripples spread far beyond where it first fell.

***A single idea becomes discovery.
Discovery becomes treatment.
And treatment changes lives.***

For more than 15 years, Snowdome has done just this – changing the lives of Australian blood cancer patients by connecting philanthropic donors with Australia’s brightest research minds.

More than 200 guests gathered under the dome on Thursday 16 October 2025 at Malvern Town Hall for another spectacular Snowball event. Guests heard first-hand about the ripple effect Snowdome has created over the past 15 years, with the first screening of *The Face of Research*, a film highlighting the impact Snowdome funding has had on the careers of leading blood cancer researchers in their pursuit of bringing next-generation treatments to patients, faster. The ripple effect was clear, as the researchers were surprised by a visit from blood cancer patients whose lives had been transformed thanks to their work.

Snowball 2025 raised \$550,000 to fund two new Fellowships, honouring two extraordinary people whose stories helped inspire the Snowdome Foundation – the Chloe Rutherford Paediatric Haematology Fellowship and the John Tandy Myeloma Haematology Fellowship.

We are truly grateful for the generosity and support of our donors, guests, committee members, event partners and sponsors who all contributed to making the night a success and helping raise vital funds for blood cancer research. We extend a special thanks to Pennie Callaghan, retiring chair of the Snowball Organising Committee.




Bridget McIntyre, Master of Ceremonies at Snowball 2025



Snowdome Board members



Snowdome co-founders Rob Tandy, Prof. Miles Prince AM, and Grant Rutherford



Snowball 2024

Funds raised at Snowball 2024 provided 30 patients across Australia with access to potentially lifesaving treatment. Thank you to everyone who supported, attended or donated to Snowball 2024 – your support made this possible.

Event Partners and Sponsors

We extend our heartfelt thanks to our event partners and supporters that contributed to the success of Snowball 2025.

Event Partners

TOWN SQUARE

dann
event
hire.



Event Sponsors



ANNA FITZPATRICK



BARRAGUNDA



SAINT HAVEN



Events

Snowdome Ladies Luncheon



Snowdome Board members
Helen Buckingham OAM,
Amanda Jones, and
Helen Gandel

On 27 February, Snowdome hosted the second annual Snowdome Ladies Luncheon at the Glasshaus Brücke in Richmond.

The luncheon provides a special opportunity for the treasured women of the Snowdome family to come together and celebrate the achievements of female researchers and clinicians.

This year, Associate Professor Melita Kenealy, a proud clinician and clinical researcher, was joined by Kylie Carter, a lymphoma patient, who shared her very personal journey with blood cancer.

Both A/Prof. Kenealy and Kylie reiterated the vital importance of research and clinical trials in improving outcomes for blood cancer patients. Had it not been for the clinical trials Kylie was able to access, her outcome may have been markedly different.

Thank you to all who supported and attended the 2025 Snowdome Ladies Luncheon.



A/Prof. Melita Kenealy
and Kylie Carter

Snowdome Board and Executive
members with family and friends

MY Mount Eliza

On 16 March, hundreds of people came together at Mount Eliza Regional Park for the annual MY Mount Eliza Run & Fun Festival.

In its ninth year, the event raised \$55,000 to support multiple myeloma research. Since its inception, it has raised more than \$500,000 for the Snowdome Foundation, helping to fund two innovative myeloma research projects.

Event founder Geoff Nyssen, who was diagnosed with myeloma in 2014 at the age of 40, is an active and successful advocate for the importance of blood cancer research and clinical trials.



New Fellowships

Honouring the Past and Funding the Future of Blood Cancer Research

The stories of Chloe Rutherford and Dr John Tandy were catalysts for the establishment of the Snowdome Foundation. This year, both Chloe and John were honoured by Snowdome with Fellowships announced in their names.

*Chloe Rutherford
Paediatric
Haematology
Fellowship*

*John Tandy
Myeloma
Haematology
Fellowship*

In 2007, Chloe Rutherford was diagnosed with leukaemia. Chloe seemingly beat the disease only to relapse and pass away from complications from pneumonia in 2009.

Snowdome was named in honour of Chloe, emerging from a case of mistaken identity rather than a flash of inspiration, but it is entirely fitting.

On one of the first of over 250 visits to the Royal Children's Hospital, Chloe thought she saw a gift shop, with snowdomes from all over the world adorning its glass walls.

It was in fact, the nurses' station where she was having surgery. To Chloe it was beautiful and magical, and like all things beautiful, she just had to have a snowdome of her own. Of course, she got what she wished, and as she bravely underwent each treatment for her cancer, more and more snowdomes appeared; gifts from family, from friends both old and new and from the nurses who cared for her.

Chloe left an indelible mark on everyone who knew her, and her story became part of a spark for something bigger, inspiring hope and changing the lives of thousands of blood cancer patients.

The Chloe Rutherford Paediatric Haematology Fellowship honours Chloe's memory and will fund critical research into paediatric blood cancers to help ensure that children and their families do not have to endure the same devastating journey.



In 2009, Dr John Tandy received the shattering news that he had myeloma, an incurable blood cancer. At the time, John was a busy GP dedicated to caring for patients at his practice in Bayside Melbourne. Like his patients with myeloma whom he had cared for, he knew that his prognosis was not good. John's life expectancy was three to five years.

Just four weeks prior to John's diagnosis, he and his wife Pam welcomed their first grandchild, Will. Will's dad, Rob Tandy, was driven by the desperate desire for his son to grow up knowing what a great person his grandfather was and within a matter of months he had connected with Professor Miles Prince AM and Chloe Rutherford's dad, Grant Rutherford. Together, Rob, Miles and Grant went on to start the Snowdome Foundation, all personally motivated to find a cure for blood cancer.

As a result of investment into research and clinical trials, John lived well beyond the three to five years initially expected, providing him with time to create precious memories with his family. Not only did John get to see his first grandchild, Will, grow into a 13-year-old teenager, but he also was able to welcome a further eight grandchildren into the family.

The John Tandy Myeloma Haematology Fellowship pays tribute to John, recognising that his story embodies what is possible when research progresses, giving blood cancer patients the chance to live longer, better lives.



Financials 2024–25

The Snowdome Foundation is a leading not-for-profit organisation focused exclusively on raising funds to support translational research and clinical trials. Since inception in 2010, the Group has raised \$69.5 million for blood cancer research.

The Snowdome Group has concluded Fiscal25 with a result that saw a balance sheet position which continues to remain very strong.

With high levels of liquidity maintained with a net assets balance of \$7.319 million. The Group's results in Fiscal25 saw a deficit of \$0.626 million, while reflecting grant payments of \$2.945 million (up \$0.686 million on prior year's level) and total income being slightly down on last year.

The Group's reported accounts which show a deficit in Fiscal25 compared to a surplus in Fiscal24, is mainly due to the timing of committed grant payments expected in Fiscal24 that now became due in Fiscal25.

While overall donations were slightly down year on year, fundraising income increased by 10 per cent in Fiscal25, with all other income amounts remaining in line with Fiscal24. Overall, expenses continued to be tightly managed.

The Group remains in a strong position to support its grants pipeline, with the majority of grants having fully funded commitments in place, and most grants having at least two years of prefunding already committed.

Further, the Snowdome Group has a financial reserve that covers one year's wages and operating expenses, equating to \$1.1 million. This provides assurance to all financial contributors that Snowdome is strongly positioned to ensure its ongoing financial viability and that donors can be confident that their donations will be invested as intended, in support of blood cancer research.

Snowdome has had another successful year in maintaining all existing grants, as well as offering new grants during the fiscal year. During Fiscal25, a total of \$2.9 million of research grant funding was paid.

Since inception, Snowdome has funded 84 research grants, enabling 105 funded research positions.

Legal Structure

The Snowdome entity consists of Snowdome Foundation Limited DGR (Deductible Gift Recipient) Item 1 and Snowdome Limited DGR Item 2. As a result, the Snowdome entity can accept tax deductible donations from all donors including Private Ancillary Funds. From Fiscal23, Snowdome Foundation Limited DGR1 entity became the principal group member in terms of fundraising for all new grant activity.

Governance

Throughout the year, the Snowdome Grants Committee reviews and recommends strategic projects to be funded. We are mindful that many of our grants are multi-year research projects. As such, we seek to fund them with multi-year donations to provide certainty of funds. We start the process by first attaining the donation commitment and then extending the grant commitment.

All grants provided have clear, measurable key performance targets which are reviewed every six months by the Snowdome Grants Committee.

The Snowdome Finance, Audit and Risk Committee oversees financial performance to minimise risk for the organisation.

Financial Year 2025 (FY25) Accounts

Snowdome's financial year accounts have been audited and submitted to the Australian Charities and Not-for-Profit Commission (ACNC).

Notwithstanding the general business uncertainties and rising inflation, Snowdome's donors generously supported us in Fiscal25.

Snowdome has continued to meet all financial commitments including grant commitments, with \$2.9 million invested in Australian blood cancer research grants in Fiscal25, a 30 per cent increase on Fiscal24.

Highlights of the 2025 financial year include:

Pro Bono Support of

\$444,248

Snowdome continues to be well supported by our incredibly generous pro bono partners with a total of \$0.444 million donated during the fiscal year.

We are very thankful for their ongoing commitment.

Granting of


\$2.9M

to blood cancer research.

During the financial year Snowdome granted \$2.9 million.


As of July 2025, Snowdome has \$4.5 million in future grant commitments, all cash backed to be paid in future financial years.

Revenue raised by Snowdome from inception to the end of FY25: **\$69.5 million.**



- *Matched \$19.90M
- #Directed \$1.07M
- ^Other \$1.56M
- Snowdome \$47M

Research funded through Snowdome from inception to the end of FY25: **\$57 million.**




- *Matched \$19.90M
- #Directed \$1.07M
- Snowdome \$36M

Pharmaceutical grant funding for the Australasian Lymphoma Alliance has not been included in the figures above (\$599K).

*Matched – Funding support matched by collaborative partners.
 #Directed – When Snowdome donations are paid directly to the administering organisation.
 ^Other – Interest earned via Term Deposits and general miscellaneous income.


Revenue received during the FY25: **\$3.58 million.**




- Interest and Other \$298K
- Snowdome \$3.28M

Pharmaceutical grant funding for the Australasian Lymphoma Alliance has not been included in the figures above (\$88K).

Income breakdown financial year 2025



Expense breakdown financial year 2025



Income and expense breakdowns exclude reference to any Australasian Lymphoma Alliance income or expenses.

Financials

Income Statement For The Year Ended June 30 2025	Snowdome Ltd ATF Snowdome Foundation (DGR2)	Snowdome Foundation Limited (DGR1)	Consolidated 2025	Consolidated 2024
Income (\$Aust)				
Donations	190,200	2,162,533	2,352,733	2,834,957
Fundraising Events		831,637	831,637	753,952
ALA Income	–	88,525	88,525	106,785
Pro Bono Goods / Services Received	–	444,248	444,248	388,892
Interest	2,011	296,149	298,160	290,882
Bequests	–	100,023	100,023	–
Other Income	–	–	–	1,906
Total Income	192,211	3,923,115	4,115,326	4,377,374
Expenses				
Grants to Organisations	(14,715)	(2,930,770)	(2,945,485)	(2,259,051)
Fundraising Events	–	(232,675)	(232,675)	(235,111)
Employee Benefits	–	(870,103)	(870,103)	(662,983)
ALA Expenses	–	(84,769)	(84,769)	(87,496)
Pro Bono Goods / Services Expenses	–	(444,248)	(444,248)	(388,891)
Depreciation and Amortisation	–	(17,147)	(17,147)	(17,173)
Other Expenses	(1,266)	(146,292)	(147,558)	(133,885)
Total Expenses	(15,981)	(4,726,004)	(4,741,985)	(3,784,590)
Surplus / (Deficit) For The Year	176,230	(802,889)	(626,659)	592,784

Statement of Financial Position As at 30 June 2025	Snowdome Ltd ATF Snowdome Foundation (DGR2)	Snowdome Foundation Limited (DGR1)	Consolidated 2025	Consolidated 2024
Assets (\$Aust)				
Current Assets				
Cash and Cash Equivalents	273,711	7,003,592	7,277,303	7,893,786
Trade and Other Receivables	501	75,124	75,625	63,315
Total Current Assets	274,212	7,078,716	7,352,928	7,957,101
Non-Current Assets				
Plant & Equipment	–	8,534	8,534	2,852
Intangible Assets	–	38,778	38,778	52,902
Total Non-Current Assets	–	47,312	47,312	55,754
Total Assets	274,212	7,126,028	7,400,240	8,012,855
Liabilities				
Current Liabilities				
Trade and Other Payables	–	15,533	15,533	8,319
Provisions	–	33,580	33,580	30,284
Other Liabilities	–	–	–	–
Total Current Liabilities	–	49,113	49,113	38,603
Non-Current Liabilities				
Provisions	–	31,817	31,817	28,283
Total Non-Current Liabilities	–	31,817	31,817	28,283
Total Liabilities	–	80,930	80,930	66,886
Net Assets	274,212	7,045,098	7,319,310	7,945,969
Funds				
Settled Sum	100	–	100	100
Retained Surpluses	274,112	7,045,098	7,319,210	7,945,869
Total Funds	274,212	7,045,098	7,319,310	7,945,969

Board

The Snowdome Board of Directors consists of twelve independent non-executive directors and one executive director.

Our passionate, skilled and highly engaged directors bring diverse experiences and expertise from various industries and sectors. They are our governing body, ensuring Snowdome realises its mission through responsibility for our strategic direction, establishing goals for management and achieving these through various committees. We also acknowledge the ongoing support of our board alumni.



John Salvaris
BEc CA CPA

Chair

Partner of KPMG specialising in corporate tax matters for financial services organisations.

John joined the Snowdome Board in 2017 and became the Chairman in 2020.



Prof Richard Boyd
BSc (Hons) PhD

Chief Scientific Advisor of Cartherics Pty Ltd, a cancer immunotherapy company.

Richard joined the Snowdome Board in 2015.



Helen Buckingham OAM
BA Dip Ed Grad Dip
Careers AICD Dip

Helen offers a personal perspective living with multiple myeloma since 2004. Helen was elected to the Legislative Council of the Victorian Parliament in 2002 and has been involved with Snowdome since its inception in 2010.



Helen Gandel

Pharmacist and philanthropist supporting a variety of community charities.

Helen joined the Snowdome Board in 2016.



Mark Inston

Partner, Banking and Finance, Hall & Wilcox. Mark is the Chair of the Snowdome Lymphoma Governance Committee and a member of Snowdome's Finance, Audit and Risk Committee, both positions he has held since 2019.

Mark joined the Snowdome Board in 2024.



Amanda Jones
BAppSc Grad Dip IP Law
FIPTA

IP Professional and former Medical Scientist. Medical Research Future Fund (MRFF) Grant Proposal Manager, University of Melbourne. Amanda has a personal connection to blood cancer through her mother and sister.

Amanda joined the Snowdome Board in 2014.



John Nevins
BEcon GDipPubPol MAICD

John is semi-retired and has previously worked in Victorian local government, public transport and the Victorian Public Service. John offers a personal perspective living with leukaemia.

John joined the Snowdome Board in 2023.



Dr Andrew Pascoe
MBBS

Executive Chairman of the Asia Pacific eHealth Group (APeHG).

Andrew joined the Snowdome Board in 2013.



Prof Miles Prince AM
MBBS (Hons) MD FRACP
FRCPA AFRCMA MACD
FAHMS

Blood cancer specialist and a Professor of Medicine at both Melbourne and Monash Universities, Professor/Director of Molecular Oncology and Cancer Immunology at Epworth Healthcare, Haematologist at the Peter MacCallum Cancer Centre and Director of the Epworth Centre for Immunotherapies & Snowdome Laboratories.

Miles is a co-founder of the Snowdome Foundation.



Grant Rutherford
BA Graphic Design

Co-founder and director of East of Everything. Grant is Chloe Rutherford's father, for whose love of snowdomes (during her leukaemia treatment) the Foundation is lovingly named.

Grant is a co-founder of the Snowdome Foundation.



Rob Tandy
BSc MPC

Facilitator from the tourism, investments and property industries. Rob brings a personal perspective of blood cancer lived through his father's diagnosis of multiple myeloma.

Rob is a co-founder of the Snowdome Foundation.



Anna Whitlam
BBus (HR & Marketing)
GAICD

CEO, WhitlamCo., an APAC executive search and advisory firm specialising in the functions that build reputation, trust and stakeholder value.

Anna joined the Snowdome Board in December 2023 and was on leave of absence in 2025.

Executive

Our team is comprised of talented, generous and committed people, driven by making a difference to the lives of those affected by blood cancer.

In 2025, we welcomed talented people into our team, strengthening our expertise in finance, fundraising, marketing and stakeholder relations. New team members bring with them a wealth of fresh perspectives and ideas to the

Snowdome Foundation, enhancing our capability to Make Hope Real for Australian blood cancer patients.

The Snowdome Foundation would like to extend a special thank you to Kirstee Macbeth, who stepped

down as Chief Executive at the end of 2025. We would also like to acknowledge and thank Marlena Assenza, Jess Bucci, Vanessa Cohen, Sue Hunt, Karmen Lau and Dan Mars for their contributions to Snowdome during 2025.



Vincent Ramos
Chief Executive



Tanya Jörgensen
Head of Operations



Lou Johns
Donor Engagement Manager



Angie Karanikolopoulos
Finance Manager




Margaret Dandis
ALA & ATCLN Administration Manager



Elian de la Rosa Gomez
Engagement Manager (Events)

Committees



Sam Neill

Our Honorary Patron

As Honorary Patron of the Snowdome Foundation, Sam Neill is a powerful advocate for people living with blood cancer across Australia and around the world.

Sam champions Snowdome's vision of greater access to new and groundbreaking therapies and raises awareness of the urgent need for innovation in blood cancer treatment.

We are honoured that Sam lends his voice and leadership to support patients, accelerate research and advocate for equitable access to life-saving advances.

Finance, Audit and Risk Committee

- John Nevins (Chair)
- Jackson Considine
- Mark Inston
- John Salvaris

Foundation Advisory Committee

- Dr Andrew Pascoe (Chair)
- Ian Allen AM
- Helen Gandel
- Lisa Livis
- Rob Tandy
- James Wilson

Grants Committee

- Prof. Richard Boyd (Chair)
- Amanda Jones (Deputy Chair)
- Helen Buckingham OAM
- Dr Anna Kalf
- Dr Olivia Milne
- Dr Andrew Pascoe

- Prof. Eliza Hawkes
- Dr Anna Johnston
- Prof. Miles Prince AM

Snowball Committee

Steering Committee

- Rob Tandy (Chair)
- Helen Gandel
- Dr Andrew Pascoe

Organising Committee

- Pennie Callaghan (Chair, to October 2025)
- Helen Gandel
- Vanessa Cohen
- Lauren Frazer
- Georgie Larkins

Remuneration Committee

- John Salvaris (Chair)
- Amanda Jones
- Rob Tandy
- Anna Whitlam

Lymphoma Governance Committee

- Mark Inston (Chair)
- Prof. Chan Cheah
- Dr Pietro Di Ciaccio
- Dr Greg Hapgood

Partners and Collaborators

Supported by the Snowdome Foundation



Collaborators

To advance blood cancer research and make hope real for Australian blood cancer patients, Snowdome Foundation is proud to collaborate with:



Children's Cancer Institute
Mater Research
Mayo Clinic

Peter MacCallum Cancer Centre
Monash University

QIMR Berghofer Medical Research Institute
University of Melbourne

University of New South Wales
University of Queensland

Pro bono partners and supporters

The ongoing generosity of these organisations allows the Snowdome Foundation to optimise the allocation of funds towards the advancement of medical research for blood cancer.



THE ANDREWS GROUP

CHRIS BUDGEON



TOWN SQUARE



ESG Compliance

The Snowdome Foundation is committed to creating a positive impact in all areas of our business. Our Environmental, Social and Governance (ESG) statement reflects our dedication to responsible, sustainable and ethical practices and behaviours.

Environmental

Acknowledging our environmental responsibilities, we are committed to minimising our carbon, water and waste footprint and promote sustainable practices that reduce impact on the environment. Our strategies include encouraging the use of public transport to and from the workplace, limiting hard copy printing, using environmentally friendly paper, recycling and separating waste, and using environmentally friendly cleaning products.

Social

We value diversity, equality and inclusion, fostering a safe, supportive and inclusive environment for our staff, board directors, partners, researchers, clinicians, committee members and volunteers. These values are reflected in the following ways:

- The gender diversity of our board and executive (53 per cent female and 47 per cent male)
- We have supported and embraced the integration of people with disabilities in our workplace. We have worked together with

external employment services to provide employment opportunities for people with disabilities with outstanding results.

- We work with suppliers that share similar values, including Flagstaff Printing, a not-for-profit Australian Disability Enterprise dedicated to providing life skills and work opportunities for people with disabilities.
- We support flexible working arrangements to enhance employee well-being, work-life balance, and inclusion. These arrangements enable individuals with caregiving responsibilities or specific needs to participate fully in our workplace and also reduces commuting which indirectly lowers carbon emissions.

Governance

We have a strong governance structure with clear reporting lines and well documented and practiced policies and procedures for operations.

We have a diverse and skills-based Board that works closely with the Executive, meet at least eight times per year and regularly assess

finance and risk. We have multiple sub-committees that each have a charter and comprise external independent members, that meet at least three times per year and report to the Board.

Our governance practices adhere to the highest ethical standards, ensuring transparency, accountability and responsible decision-making. We are committed to continual review and improvement processes and engage external parties to audit and review financials and strategy. A reflection of our commitment in this area is the return of a clean audit in 2025. Our rigorous adherence to cyber care is a priority for Snowdome with continuous review of all requirements to ensure the integrity and safety of the data we hold.

ESG principles are part of our core values to fulfil our mission to accelerate next-generation treatments for Australian blood cancer patients to help them live longer, better lives.

Thank You

After more than five years of dedicated leadership and outstanding service, Kirstee Macbeth concluded her tenure as Snowdome's Chief Executive at the end of 2025.

Snowdome remains immensely grateful for Kirstee's leadership, vision and energy. Under her stewardship, Snowdome achieved significant milestones; growing our fundraising impact, expanding our reach within the blood cancer space and strengthening our partnerships with researchers, clinicians and donors.

During Kirstee's tenure, Snowdome made remarkable progress in our mission to accelerate access to blood cancer treatments and improve outcomes for patients and their families.

Our thanks

The Taboo Group who worked tirelessly to bring this review to life and to photographer Chris Budgeon, who generously captured our people this year.

Acknowledgement of Country

The Snowdome Foundation acknowledges the Wurundjeri people of the Kulin Nation as the Traditional Owners of the land on which we live and work. We celebrate their living connection to Country and enduring relationship to land and waters. We acknowledge and pay respects to Elders, past and present.

Dedication

The Snowdome Foundation is dedicated to all those that have been touched by or affected by blood cancer.

In August 2025, we sadly bid farewell to Andrew 'Drew' Lean, a cherished member of the Snowdome family who is sorely missed.

We also wish to honour the memory of Yueh-Chuan Yu who passed away this year.

The support of Drew, Yueh-Chuan and their families has contributed to vital blood cancer research, offering hope to countless Australian blood cancer patients.



Making hope real

© 2026

SNOWDOME, the Snowdome logo and 'Making Hope Real' are trademarks of Snowdome Foundation Limited.

Snowdome Limited (DGR 2) – ABN 26 239 780 877

Snowdome Foundation Limited (DGR 1) – ABN 79 624 141 117



**Snowdome
Foundation™**

www.snowdome.org.au